Spotlight: Celltrion's Remicade biosim kneecapped Merck in Europe

The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's ($PFE) Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson ($JNJ) that it's been stealing in Europe from Merck & Co. ($MRK)? Depends who you ask. More from FiercePharma

> Johnson & Johnson ($JNJ) inked a $85 million deal to develop and sell Tesaro's experimental prostate cancer pill niraparib. Report

> Amphastar Pharmaceuticals ($AMPH), which has come in for criticism for the price of its overdose antidote naloxone, agreed to give Connecticut a $6 rebate for each dose purchased by a state or municipal agency. Report

> The cost of insulin treatments for diabetes rose by nearly 200% from 2002 to 2013, the Journal of the American Medical Association reports, as expensive new analog treatments supplanted older human insulins. Report

> Shire ($SHPG) released top-line Phase III data on its ADHD drug candidate SHP465 showing that the drug met its primary goal for improving symptoms in children and adolescents. Report

> Hedge funder Bill Ackman is set to explain a 25% quarterly loss to his investors Wednesday, with his bad bet on Valeant Pharmaceuticals ($VRX) first in line. Report

And Finally... Worldwide diabetes cases hit 422 million as the disease mushrooms in the developing world. Report

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.